PFIZER INC. (LON:PFZ) Files An 8-K Regulation FD Disclosure

PFIZER INC. (LON:PFZ) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

On December 19, 2018, Pfizer Inc. (“Pfizer”) issued a press release announcing that Pfizer, GlaxoSmithKline plc (“GSK”) and GlaxoSmithKline Consumer Healthcare Holdings Limited, a wholly owned subsidiary of GSK, entered into an agreement to which, on the terms and subject to the conditions contained therein, Pfizer and GSK agreed to combine their respective consumer healthcare businesses to form a new consumer healthcare joint venture.

The press release announcing the proposed transaction is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 7.01 Financial Statements and Exhibits.



EX-99.1 2 pressreleaseexh.htm EXHIBIT 99.1 PFIZER INC. PRESS RELEASE Exhibit  Exhibit 99.1 For immediate release:  Pfizer U.S. Media contact:December 19,…
To view the full exhibit click here

An ad to help with our costs